Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown

Nature Protocols

Volumn 11, Issue 1, 2016, Pages 22-36

  Bäumer, Nicole ^a   Appel, Neele ^a   Terheyden, Lisa ^a   Buchholz, Frank ^b   Rossig, Claudia ^a   Müller Tidow, Carsten ^a,c   Berdel, Wolfgang E ^a   Bäumer, Sebastian ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID; CARRIER PROTEIN; CELL SURFACE RECEPTOR; CYCLOHEXANE; CYSTEINE; HYBRID PROTEIN; IMMUNOGLOBULIN G; MESSENGER RNA; PROTAMINE; SMALL INTERFERING RNA; ANTIBODY; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR; MALEIMIDE DERIVATIVE; SULFOSUCCINIMIDYL 4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBOXYLATE;

ARTICLE; CONTROLLED STUDY; CROSS LINKING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECEPTOR BINDING; RNA INTERFERENCE; WESTERN BLOTTING; ANIMAL; CHEMISTRY; GENE SILENCING; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; DRUG CARRIERS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALEIMIDES; MICE; PROTAMINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84949442842     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2015.137     Document Type: Article

References (27)

1. Bäumer, S. et al. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin. Cancer Res. 21, 1383-1394 (2015).
2. Choi, Y.S. et al. The systemic delivery of siRNAs by a cell penetrating peptide, low-molecular-weight protamine. Biomaterials 31, 1429-1443 (2009).
3. El-Andaloussi, S. et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 7, 2112-2126 (2012).
4. Liu, B. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA. Brief. Funct. Genomics Proteomics 6, 112-119 (2007).
5. Hsu, C.Y. & Uludag, H. A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine. Nat. Protoc. 7, 935-945 (2012).
6. Di Paolo, D. et al. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol. Ther. 19, 2201-2212 (2011).
7. Casi, G. & Neri, D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J. Control. Release 161, 422-428 (2012).
8. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005).
9. Kies, M.S. & Harari, P.M. Cetuximab (Imclone/Merck/Bristol-Myers Squibb). Curr. Opin. Investig. Drugs 3, 1092-1100 (2002).
10. Hauser, P.V. et al. Novel siRNA delivery system to target podocytes in vivo. PLoS ONE 5, e9463 (2010).
11. Yao, Y.D. et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl. Med. 4, 130ra48 (2012).
12. Peer, D., Zhu, P., Carman, C.V., Lieberman, J. & Shimaoka, M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad. Sci. USA 104, 4095-4100 (2007).
13. Kittler, R. et al. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat. Methods 4, 337-344 (2007).
14. Tap, W.D. et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J. Clin. Oncol. 30, 1849-1856 (2012).
15. Mayeenuddin, L.H., Yu, Y., Kang, Z., Helman, L.J. & Cao, L. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and bcl-x(L). Oncogene 29, 6367-6377 (2010).
16. Steele-Perkins, G. & Roth, R.A. Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding. Biochem. Biophys. Res. Commun. 171, 1244-1251 (1990).
17. Zia, F. et al. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J. Cell. Biochem. Suppl. 24, 269-275 (1996).
18. Gargiulo, G., Serresi, M., Cesaroni, M., Hulsman, D. & van Lohuizen, M. In vivo shRNA screens in solid tumors. Nat. Protoc. 9, 2880-2902 (2014).
19. Burnett, J.C., Rossi, J.J. & Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6, 1130-1146 (2011).
20. Tabernero, J. et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406-417 (2013).
21. Kumar, P. et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134, 577-586 (2008).
22. Surendranath, V., Theis, M., Habermann, B.H. & Buchholz, F. Designing efficient and specific endoribonuclease-prepared siRNAs. Methods Mol. Biol. 942, 193-204 (2013).
23. Deacon, R.M. Housing, husbandry and handling of rodents for behavioral experiments. Nat. Protoc. 1, 936-946 (2006).
24. Schmidt, L.H. et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J. Thorac. Oncol. 6, 1984-1992 (2011).
25. Bäumer, N. et al. A limited role for the cell cycle regulator cyclin A1 in murine leukemogenesis. PLoS ONE 10, e0129147 (2015).
26. Bäumer, N. et al. Retinal pigmented epithelium determination requires the redundant activities of Pax2 and Pax6. Development 130, 2903-2915 (2003).
27. Di Scipio, F., Raimondo, S., Tos, P. & Geuna, S. A simple protocol for paraffin-embedded myelin sheath staining with osmium tetroxide for light microscope observation. Microsc. Res. Tech. 71, 497-502 (2008).